Letrozol Genthon

Letrozole, the active ingredient in Letrozol Genthon, is an aromatase inhibitor presented as an oral tablet for oral use. It reduces estrogen production and is employed in the treatment of hormone‑sensitive breast cancer in postmenopausal women.

GNH USA supplies Letrozol Genthon as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to EU quality standards and provides the product to hospitals, pharmacies and clinical trial sites across multiple regions. Its distribution network includes Europe, Asia, Africa and the Americas, ensuring timely delivery to qualified healthcare institutions.

Letrozole is used in the management of estrogen‑dependent breast cancer and related disease pathways. - Postmenopausal breast cancer: reduces tumor growth by lowering circulating estrogen levels. - Hormone‑sensitive breast cancer: slows disease progression in estrogen‑receptor positive tumors. - Adjuvant therapy for early‑stage breast cancer: improves disease‑free survival after surgical resection.

Letrozole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint pain: aching or stiffness in knees, hips or shoulders. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild stomach upset or urge to vomit. - Headache: pressure or throbbing pain in the head. - Dizziness: light‑headedness or imbalance.

Serious or Rare Side Effects: - Severe bone loss: increased risk of osteoporosis and fractures. - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Liver toxicity: elevated transaminases or hepatitis. - Interstitial lung disease: breathing difficulties and cough. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Cardiac arrhythmia: QT interval prolongation.

Before initiating letrozole therapy, clinicians should evaluate several safety considerations. - Monitor bone health: assess bone mineral density and consider calcium/vitamin D supplementation. - Assess cardiovascular risk: evaluate history of thrombosis or clotting disorders. - Evaluate liver function: perform baseline hepatic enzymes and monitor periodically. - Avoid use in pregnancy: drug is contraindicated due to teratogenic potential. - Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Letrozole can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Estrogen replacement therapy: negates estrogen suppression. - Strong CYP3A4 inducers (e.g., rifampin): markedly reduce plasma levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase exposure and toxicity. - Tamoxifen co‑administration: may diminish therapeutic effect. - Concurrent aromatase inhibitors: duplicate pharmacologic action.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): enhanced anticoagulant effect. - SSRIs affecting platelet function: potential bleeding risk. - Statins metabolized by CYP3A4: altered concentrations. - Diuretics causing electrolyte shifts: monitor potassium. - Anticonvulsants (carbamazepine): may lower letrozole levels.